Dr. Vince Clinical Research (DVCR), a full-service contract research organization (CRO) specializing in early phase clinical development, today announced that William Lavery, MD, PhD, Principal Investigator at DVCR, is now certified by the American Board of Obesity Medicine.
The certification adds further clinical depth to DVCR’s early phase capabilities in an area of heightened Sponsor focus as obesity and obesity-related co-morbid diseases continue driving significant public health and drug development activity. According to the CDC National Center for Health Statistics, obesity impacted 40.3% of U.S. adults during 2021–2023 and remains a major risk factor for chronic diseases including type 2 diabetes and cardiovascular disease.1
“The increased knowledge and expertise brought by this certification increases DVCR’s ability to conduct various obesity related early phase clinical research studies,” said Dr. Lavery, Principal Investigator at Dr. Vince Clinical Research. “It allows DVCR to make impactful contributions to these programs while helping Sponsors generate faster, higher-quality data.”
DVCR’s infrastructure and operational capabilities support the efficient execution of metabolic studies, particularly those involving recruitment challenges, intensive monitoring and extended confinement that require specialized clinical expertise during early phase development.
“Our clinical pharmacology unit, which is one of the most luxurious and technologically advanced research centers in the world, provides us with a strategic advantage in recruiting and retaining specialty populations for complex Phase I clinical trials,” added Bradley Vince, DO, CEO and Chief Medical Officer of Dr. Vince Clinical Research. “Combined with Dr. Lavery’s certification, these capabilities position DVCR to deliver on the evolving needs of our Sponsors.”
Driven by continued innovation in obesity research, DVCR is helping Sponsors expand beyond first-generation GLP-1 therapies to evaluate broader metabolic treatment strategies, including oral agents and approaches designed to improve long-term tolerability and patient adherence.2
About Dr. Vince Clinical Research
Dr. Vince Clinical Research (DVCR) is a full-service contract research organization (CRO) specializing in early phase trials in both healthy normal volunteers and patient populations across a wide range of trial designs and therapeutic areas such as neuroscience, substance use disorders, dermatology, immunology, cardiometabolic disorders and many others. CRO services include project management, data management, biostatistics, statistical programming, PK/PD analysis and modeling, clinical and medical monitoring, medical writing, central laboratory services as well as site feasibility and management of multi-site trials with our network of site partners.
Additionally, DVCR operates one of the most innovative and technologically advanced clinical pharmacology units in the world with 100 beds for overnight confinement, a cGMP compliant pharmacy as well as luxurious amenities to support diverse study participant recruitment and retention. By leveraging technology and one of the country’s most experienced leadership teams in early clinical development, DVCR provides Smarter Faster Data® to its biopharmaceutical clients.
For more information, visit: https://drvince.com/cro
Connect with DVCR on LinkedIn and YouTube
References
1. CDC National Center for Health Statistics: Obesity and Severe Obesity Prevalence in Adults. https://www.cdc.gov/nchs/products/databriefs/db508.htm?utm_source=chatgpt.com
2. Drug Discovery World: Obesity Treatment Trends in 2026 and Beyond. https://www.ddw-online.com/obesity-treatment-trends-in-2026-and-beyond-40289-202602/
View source version on businesswire.com: https://www.businesswire.com/news/home/20260603326194/en/
Media gallery
